{
    "clinical_study": {
        "@rank": "156268", 
        "arm_group": [
            {
                "arm_group_label": "pirarubicin", 
                "arm_group_type": "Experimental", 
                "description": "3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate"
            }, 
            {
                "arm_group_label": "doxorubicin", 
                "arm_group_type": "Active Comparator", 
                "description": "8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)"
            }
        ], 
        "brief_summary": {
            "textblock": "T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the\n      patients recieved classic CHOP regimen(cyclophosphamide,vincristin,doxorubicin and\n      predisone)is less than 30%.High dose intensive chemotherapy doesn`t demonstrate better\n      response. At present, there is no standardized treatment protocol for this kind of lymphoma.\n\n      Between 1994 and 1998,the Scotland and Newcastle Lymphoma Group prospectively collected data\n      on newly diagnosed patients with enteropathy associated T-cell lymphoma (EATL)in the\n      Northern Region of England and Scotland,which is a rare and aggressive type of peripheral\n      T-cell lymphoma.The novel regimen IVE/MTX (ifosfamide, vincristine,\n      etoposide/methotrexate)-ASCT was piloted for patients eligible for intensive\n      treatment,followed by auto-stem cell transplantation.Five-years PFS and OS were 52% and 60%\n      respectively, significantly improved compared with the historical group treated with\n      anthracycline-based chemotherapy. The encouraged results were extended to the peripherial T\n      cell lymphoma-non specified(PTCL-nos).\n\n      Past studies suggested pirarubicin was more active to the T cell lymphoma than doxorubicin\n      in vitro based on its high concentration in tumor cells. Clinical data also presented\n      equivalent even superior efficacy of pirarubicin with lower toxicity than doxorubicin. The\n      aim of our study is to compare the response and survival rate of CTOP/ITE/MTX\n      (cyclophosphamide, vincristin,pirarubicin and predisone/ ifosfamide, pirarubicin,\n      etoposide/methotrexate) with those of CHOP regimen,looking forward to its superiority in\n      efficacy and safety for the de novo young patients with T cell lymphoma."
        }, 
        "brief_title": "CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ALK-negative Anaplastic Large Cell Lymphoma", 
            "Peripherial T Cell Lymphoma,Not Otherwise Specified", 
            "Angioimmunoblastic T Cell Lymphoma", 
            "Enteropathy Associated T Cell Lymphoma", 
            "Hepatosplenic T Cell Lymphoma", 
            "Subcutaneous Panniculitis Like T Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Immunoblastic Lymphadenopathy", 
                "Intestinal Diseases", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Panniculitis", 
                "Lymphoma, T-Cell", 
                "Lymphoma, Large-Cell, Anaplastic", 
                "Enteropathy-Associated T-Cell Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pathologic verified mature T cell lymphoma,including ALK-negative anaplastic large\n             cell lymphoma,peripherial T cell lymphoma-non specific type,angioimmunoblastic T cell\n             lymphoma,enteropathy associated T cell lymphoma and hepatosplenic T cell lymphoma\n\n          -  SGOT/SGPT no more than 2 times of UNL\n\n          -  serum creatinine no more than 1.5 times of UNL\n\n          -  signed informed consent\n\n        Exclusion Criteria:\n\n          -  woman in pregnancy or lactation\n\n          -  allergic to any intervention drug\n\n          -  insuitable to the study due to severe complication\n\n          -  enrolled to other study during the past 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746992", 
            "org_study_id": "CTOP"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "pirarubicin", 
                    "doxorubicin"
                ], 
                "description": "day 1 in both arms", 
                "intervention_name": "Cyclophosphamide 750mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "CTX"
            }, 
            {
                "arm_group_label": [
                    "pirarubicin", 
                    "doxorubicin"
                ], 
                "description": "day 1", 
                "intervention_name": "Vincristine 1.4mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "VCR"
            }, 
            {
                "arm_group_label": "doxorubicin", 
                "description": "day 1", 
                "intervention_name": "Doxorubicin 50mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "ADM"
            }, 
            {
                "arm_group_label": [
                    "pirarubicin", 
                    "doxorubicin"
                ], 
                "description": "day1-day5", 
                "intervention_name": "prednisone 60mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "PRED"
            }, 
            {
                "arm_group_label": "pirarubicin", 
                "description": "day 22-day 24", 
                "intervention_name": "ifosfamide 2000mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "IFO"
            }, 
            {
                "arm_group_label": "pirarubicin", 
                "description": "day 1", 
                "intervention_name": "pirarubicin 50mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "THP"
            }, 
            {
                "arm_group_label": "pirarubicin", 
                "description": "day 22", 
                "intervention_name": "pirarubicin 25mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "THP"
            }, 
            {
                "arm_group_label": "pirarubicin", 
                "description": "day 22-day 24", 
                "intervention_name": "Etoposide phosphate 100mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "VP-16"
            }, 
            {
                "arm_group_label": "pirarubicin", 
                "description": "day 43", 
                "intervention_name": "methotrexate 1500mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "MTX"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Methotrexate", 
                "Ifosfamide", 
                "Isophosphamide mustard", 
                "Etoposide phosphate", 
                "Pirarubicin", 
                "Doxorubicin", 
                "Etoposide", 
                "Prednisone", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 24, 2013", 
        "location": {
            "contact": {
                "email": "orenge@medmail.com.cn", 
                "last_name": "shu CHENG", 
                "phone": "86-21-64370045", 
                "phone_ext": "665251"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Ruijin hospital"
            }, 
            "investigator": {
                "last_name": "weili ZHAO", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma", 
        "overall_contact": {
            "email": "zhao.weili@yahoo.com", 
            "last_name": "WEILI ZHAO", 
            "phone": "86-21-64370045", 
            "phone_ext": "665251"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "complete remission rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "3-year PFS", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746992"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruijin Hospital", 
            "investigator_full_name": "Zhao Weili", 
            "investigator_title": "vice director of Department of Hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall response rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "3-year os", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Ruijin Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruijin Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}